Proteolysis Targeting Chimeras (PROTACs)
Proteolysis targeting chimeras (PROTACs) are a class of bifunctional small molecules designed to induce selective degradation of specific proteins. Unlike traditional small-molecule inhibitors that act by occupying the active sites of target proteins, PROTACs hijack the endogenous ubiquitin–proteasome system to label target proteins for degradation, thereby eliminating their function at the source. This approach opens new avenues for tackling previously undruggable targets, including non-enzymatic proteins, transcription factors lacking well-defined active sites, and mutant disease-driving proteins associated with drug resistance.
A typical PROTAC comprises three essential components: a ligand for the target protein, a ligand for an E3 ubiquitin ligase, and a linker that spatially connects the two. Within the cellular environment, the PROTAC molecule facilitates the formation of a ternary complex by simultaneously binding the target protein and the E3 ligase. This proximity enables the E3 ligase to ubiquitinate the target protein, which is then recognized and degraded by the 26S proteasome. Importantly, this process is event-driven—PROTACs do not require prolonged occupancy of the binding site, as transient engagement is sufficient to trigger protein degradation. This mechanism confers distinct pharmacological advantages, including sustained activity and improved dose control.
Endowed with high therapeutic potential, proteolysis targeting chimeras (PROTACs) have demonstrated broad applicability in oncology, neurodegenerative disorders, autoimmune diseases, and infectious diseases. As a result, they have emerged as a major focus in the field of targeted therapeutics.
The design of proteolysis targeting chimeras (PROTACs) is strategically complex and presents numerous technical challenges. Their efficacy hinges on the cooperative performance of the three modular domains, with optimization of any component markedly influencing degradation efficiency and selectivity. The target protein ligand is typically derived from known small-molecule inhibitors or modified natural products, refined through affinity screening and structure-based optimization to ensure high specificity. The E3 ligase ligand is often selected from well-characterized systems such as CRBN, VHL, or MDM2, which are broadly expressed in human tissues. Tissue-specific degradation can be enhanced by choosing E3 ligases with distinct expression profiles. The linker, meanwhile, serves as a spatial organizer, with design considerations including optimal length, conformational flexibility, polarity, and metabolic stability.
From a synthetic standpoint, proteolysis targeting chimeras (PROTACs) are generally constructed in a modular fashion, where each unit is synthesized independently and subsequently conjugated via chemical linkage. Synthetic strategies must preserve molecular integrity while tuning physicochemical attributes. In certain cases, the incorporation of reversible linkers or prodrug designs can improve pharmacokinetics and tissue permeability. Notably, several PROTACs have already demonstrated oral bioavailability and the ability to cross the blood–brain barrier, significantly expanding their clinical potential.
Despite their promise, proteolysis targeting chimeras (PROTACs) face several technical hurdles. Their relatively large molecular weight and structural complexity may limit cellular permeability and metabolic stability. Moreover, the structural compatibility between target proteins and E3 ligases—including their spatial orientation and binding affinity—remains difficult to predict using current modeling approaches, necessitating empirical validation of many candidate molecules. The kinetics and conformational dynamics of ternary complex formation are also critical to degradation efficacy, yet predictive frameworks in this area remain underdeveloped.
Drawing on deep expertise in off-target profiling of PROTAC compounds, MtoZ Biolabs is dedicated to supporting researchers with high-quality analytical services tailored to the development and characterization of targeted protein degraders.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
